NCT02392572 2026-03-12
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT05476939 2026-02-05
BIOMEDE 2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT05542407 2026-01-29
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT06012929 2026-01-26
A Study of ONC201 for Refractory Meningioma
University of Nebraska
Phase 2 Withdrawn
NCT05009992 2025-12-17
PNOC022
University of California, San Francisco
Phase 2 Recruiting
NCT05580562 2025-08-26
ACTION
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT03295396 2025-07-28
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Jazz Pharmaceuticals
Phase 2 Terminated
NCT04055649 2025-06-18
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Recruiting